• 1
    Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005; 54: 7107.
  • 2
    Shaheen NJ, Hansen RA, Morgan DR, et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 2006; 101: 212838.
    Direct Link:
  • 3
    Toghanian S, Wahlqvist P, Johnson DA, Bolge SC, Liljas B. The burden of disrupting gastro-oesophageal reflux disease: a database study in US and European cohorts. Clin Drug Investig 2010; 30: 16778.
  • 4
    Gisbert JP, Cooper A, Karagiannis D, et al. Impact of gastroesophageal reflux disease on work absenteeism, presenteeism and productivity in daily life: a European observational study. Health Qual Life Outcomes 2009; 7: 90.
  • 5
    McColl E, Junghard O, Wiklund I, Revicki DA. Assessing symptoms in gastroesophageal reflux disease: how well do clinicians' assessments agree with those of their patients? Am J Gastroenterol 2005; 100: 118.
    Direct Link:
  • 6
    Dent J, Vakil N, Jones R, et al. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. Gut 2010; 59: 71421.
  • 7
    Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 190020.
    Direct Link:
  • 8
    Hatlebakk JG. Endoscopy in gastro-oesophageal reflux disease. Best Pract Res Clin Gastroenterol 2010; 24: 77586.
  • 9
    Rubenstein JH, Taylor JB. Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther 2010; 32: 12227.
  • 10
    Malfertheiner P, Nocon M, Vieth M, et al. Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care – the ProGERD study. Aliment Pharmacol Ther 2012; 35: 15464.
  • 11
    Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135: 1392413.
  • 12
    Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135: 138391.
  • 13
    An evidence-based appraisal of reflux disease management – the Genval Workshop Report. Gut 1999; 44(Suppl. 2): S116.
  • 14
    Franco-Belgian Consensus Conference on adult gastro-oesophageal reflux disease – diagnosis and treatment. Report of a meeting held in Paris, France, 21–22 January 1999. Eur J Gastroenterol Hepatol 2000; 12: 12937.
  • 15
    Lacy BE, Weiser K, Chertoff J, et al. The diagnosis of gastroesophageal reflux disease. Am J Med 2010; 123: 58392.
  • 16
    Carlsson R, Dent J, Bolling-Sternevald E, et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998; 33: 10239.
  • 17
    Locke GR, Talley NJ, Weaver AL, Zinsmeister AR. A new questionnaire for gastroesophageal reflux disease. Mayo Clin Proc 1994; 69: 53947.
  • 18
    Shaw MJ, Talley NJ, Beebe TJ, et al.Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol 2001; 96: 527.
    Direct Link:
  • 19
    Bardhan KD, Stanghellini V, Armstrong D, Berghofer P, Gatz G, Monnikes H. Evaluation of GERD symptoms during therapy. Part I. Development of the new GERD questionnaire ReQuest. Digestion 2004; 69: 22937.
  • 20
    Jones R, Junghard O, Dent J, et al.Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther 2009; 30: 10308.
  • 21
    Ponce J, Garrigues V, Agreus L, et al.Structured management strategy versus usual care for gastroesophageal reflux disease: rationale for pooled analysis of five European cluster-randomized trials. Therap Adv Gastroenterol 2011; 4: 1126.
  • 22
    Jones R, Coyne K, Wiklund I. The gastro-oesophageal reflux disease impact scale: a patient management tool for primary care. Aliment Pharmacol Ther 2007; 25: 14519.
  • 23
    Revicki DA, Wood M, Wiklund I, Crawley J. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res 1998; 7: 7583.
  • 24
    Lundell LR, Dent J, Bennett JR, et al.Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 17280.
  • 25
    Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 261620.
    Direct Link:
  • 26
    Giannini EG, Zentilin P, Dulbecco P, Vigneri S, Scarlata P, Savarino V. Management strategy for patients with gastroesophageal reflux disease: a comparison between empirical treatment with esomeprazole and endoscopy-oriented treatment. Am J Gastroenterol 2008; 103: 26775.
    Direct Link:
  • 27
    Hatlebakk JG, Hyggen A, Madsen PH, et al. Heartburn treatment in primary care: randomised, double blind study for 8 weeks. BMJ 1999; 319: 5503.
  • 28
    Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011; 365: 137583.